alexion convers ultomiri ahead schedul share
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim
price data jul
rate updat jul
currenc amount express
methodolog valu compani
oper result total revenu billion
last year soliri approv four rare
diseas contribut million revenu
last year soliri double-digit volum growth off-set
price headwind canada may small
impact rest year metabol drug strensiq
kanuma post double-digit growth
contribut million follow quarter strong
result manag rais guidanc full year
may make adjust model
anticip materi chang fair valu estim
pleas see ultomiri surpass
expect million revenu second
quarter doubl revenu first quarter
manag report paroxysm nocturn
hemoglobinuria pnh patient switch
soliri approach patent expir ultomiri
offer conveni dose schedul everi
two month slightli lower price mean alexion
track well goal convert pnh patient
ultomiri end success patient
convers soliri ultomiri remain key pillar
narrow moat rate believ alexion
abl avoid sever sale declin despit inevit
biosimilar entri patient hesit switch
back soliri inconveni dose schedul everi two
compani sever advanc clinic trial initi
includ phase superior trial
wilson diseas phase trial
warm autoimmun hemolyt anemia
phase trial al amyloidosi
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria atyp hemolyt
urem syndrom gener myasthenia gravi next-gener
ultomiri recent approv paroxysm nocturn hemoglobinuria
strensiq kanuma target ultrarar metabol diseas alexion
rare diseas high unmet need
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
expect research develop cost grow
doubl digit year remain total
revenu medium term
compani announc addit already-
abund pipelin clinic trial plan initi
phase trial ultomiri hematopoiet stem cell
thrombot microangiopathi
hsct-tma seriou complic stem cell transplant
approv treatment option may
off-label use alexion therapi indic
alexion share earli trial result
yet includ model competitor
narsoplimab nomacopan coversin
alreadi trial way hsct-tma alexion
experi clinic develop compar
small competitor suggest compani could catch
quickli expand address patient
popul ultomiri
give littl credit rest alexion pipelin
model point given mani candid still
earli stage includ plan trial
gener myasthenia gravi ultomiri primari
progress multipl sclerosi amyotroph later
sclerosi overal compani focu rare
diseas high unmet need strong price power
see path continu excess return support
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
